iBio, Inc. Common Stock (IBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, iBio, Inc. Common Stock (IBIO) has a cash flow conversion efficiency ratio of -0.093x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.24 Million) by net assets ($56.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See iBio, Inc. Common Stock defensive interval ratio to measure how many days the company can operate on defensive assets alone.
iBio, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how iBio, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
iBio, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of iBio, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bilici Yatirim Sanayi ve Ticaret AS
IS:BLCYT
|
-0.021x |
|
RBZ Jewellers Limited
NSE:RBZJEWEL
|
-0.056x |
|
Mgame Corp
KQ:058630
|
-0.004x |
|
Beijing North Star Company Limited
F:BJ3
|
0.078x |
|
PP Properti Tbk PT
JK:PPRO
|
0.001x |
|
Jooyontech
KO:044380
|
0.014x |
|
NTPM Holdings Bhd
KLSE:5066
|
0.027x |
|
Thantawan Industry Public Company Limited
BK:THIP
|
-0.005x |
Annual Cash Flow Conversion Efficiency for iBio, Inc. Common Stock (2007–2025)
The table below shows the annual cash flow conversion efficiency of iBio, Inc. Common Stock from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see iBio, Inc. Common Stock stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $14.88 Million | $-15.30 Million | -1.028x | -18.20% |
| 2024-06-30 | $21.32 Million | $-18.55 Million | -0.870x | +56.03% |
| 2023-06-30 | $15.38 Million | $-30.44 Million | -1.979x | -232.32% |
| 2022-06-30 | $63.48 Million | $-37.80 Million | -0.595x | -115.03% |
| 2021-06-30 | $108.57 Million | $-30.06 Million | -0.277x | -17.46% |
| 2020-06-30 | $56.61 Million | $-13.35 Million | -0.236x | +95.86% |
| 2019-06-30 | $2.46 Million | $-13.97 Million | -5.688x | -582.03% |
| 2018-06-30 | $16.16 Million | $-13.48 Million | -0.834x | +43.52% |
| 2017-06-30 | $8.91 Million | $-13.16 Million | -1.477x | -339.80% |
| 2016-06-30 | $24.04 Million | $-8.07 Million | -0.336x | +20.20% |
| 2015-06-30 | $11.23 Million | $-4.72 Million | -0.421x | +37.66% |
| 2014-06-30 | $6.10 Million | $-4.12 Million | -0.675x | +29.47% |
| 2013-06-30 | $5.07 Million | $-4.85 Million | -0.957x | +1.78% |
| 2012-06-30 | $6.17 Million | $-6.01 Million | -0.974x | +96.41% |
| 2011-06-30 | $196.64K | $-5.34 Million | -27.147x | -1144.06% |
| 2010-06-30 | $1.08 Million | $-2.35 Million | -2.182x | -372.91% |
| 2009-06-30 | $4.39 Million | $-2.02 Million | -0.461x | -348.99% |
| 2008-06-30 | $-6.20 Million | $-1.15 Million | 0.185x | -5.46% |
| 2007-06-30 | $-4.33 Million | $-849.38K | 0.196x | -- |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu,… Read more